Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 6
Submit an article Journal homepage
267
Views
3
CrossRef citations to date
0
Altmetric
Nephrology

Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma

Xue SongIBM Watson Health, Cambridge, MA, USA; Correspondence[email protected]
,
Qayyim SaidNovartis Pharmaceutical Corporation, East Hanover, NJ, USA;
,
Oth TranIBM Watson Health, Cambridge, MA, USA;
,
Darcy A. KruegerDivision of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA;
&
John BisslerLeBonheur Children’s Hospital and St. Jude Children’s Research Hospital, Memphis, TN, USA
Pages 1103-1110 | Received 27 Jun 2018, Accepted 11 Dec 2018, Published online: 14 Jan 2019

References

  • Budde K, Gaedeke J. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. Am J Kidney Dis. 2012;59(2):276–283.
  • Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657–668.
  • Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics. 2010;41(5):199–208.
  • National Institute of Neurological Diseases and Stroke (NINDS). Tuberous Sclerosis Fact Sheet [Internet]. 2017 [cited 2018 Apr 14]. Available from: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Tuberous-Sclerosis-Fact-Sheet
  • Baskin HJ Jr. The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol. 2008;38(9):936–952.
  • Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125–127.
  • Rosser T, Panigrahy A, McClintock W. The diverse clinical manifestations of tuberous sclerosis complex: a review. Semin Pediatr Neurol. 2006;13(1):27–36.
  • Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255–265.
  • Adriaensen ME, Schaefer-Prokop CM, Stijnen T, et al. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol. 2009;16(6):691–696.
  • Campen CJ, Porter BE. Subependymal giant cell astrocytoma (SEGA) treatment update. Curr Treat Options Neurol. 2011;13(4):380–385.
  • Franz DN, Agricola K, Mays M, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78(6):929–938.
  • Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 2011;118(1):e15–20.
  • Eijkemans MJ, van der Wal W, Reijnders LJ, et al. Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am J Kidney Dis. 2015;66(4):638–645.
  • Kingswood JC, Bissler JJ, Budde K, et al. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: current data and future study. Nephron. 2016;134(2):51–58.
  • Afinitor (everolimus) and Afinitor Disperz (everolimus tablets for oral suspension). Prescribing information [Internet]. 2016 [cited 2018 Apr 14]. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/afinitor.pdf [Last accessed April 14, 2018]
  • Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–132.
  • Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801–1811.
  • Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–824.
  • Kingswood JC, Jozwiak S, Belousova ED, et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial EXIST-1. Nephrol Dial Transplant. 2014;29(6):1203–1210.
  • Krueger DA, Care MM, Agricola K, et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80(6):574–580.
  • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
  • Princic N, Brouillette M, Tang DH, et al. Analysis of real world patient compliance to everolimus-based therapy among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer (mBC). Poster presented at: American Society of Clinical Oncology (ASCO) 2017 Annual Meeting; Chicago, IL.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.